Weed Giant Curaleaf Acquires London-Based Medical Marijuana Company EMMAC
On Tuesday, March 9th, Curaleaf Holdings announced it had signed an ironclad agreement to acquire EMMAC Life Sciences Limited for nearly $286 million 85% to be paid in Curaleaf shares and 15% in cash.
The acquisition gives Curaleaf a defined lead against other U.S. operators in the European cannabis market. Curaleaf CEO Joseph Bayern commented that the agreement “marks a milestone moment as Curaleaf will immediately become the U.S. multi-state operator with the largest European footprint. Our acquisition of EMMAC will provide a strong platform for the future introduction of our Curaleaf and Select brands into the European market, all leveraging our science, R&D, formulated product and form factor innovations, as well as vast consumer insights that we have built through our leadership position in the U.S.”
Up and down: Lawsuits, fake websites, odourless tobacco and a really big U S /Europe deal
leaderpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from leaderpost.com Daily Mail and Mail on Sunday newspapers.
Up and down: Lawsuits, fake websites, odourless tobacco and a really big U S /Europe deal
canoe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from canoe.com Daily Mail and Mail on Sunday newspapers.
Curaleaf to Enter European Cannabis Market with Acquisition of EMMAC Life Sciences Limited - Europe s Leading Independent Cannabis Company EMMAC Brings the Largest Vertically Integrated Independent Cannabis Company in Europe with a Presence in Key European Medical Cannabis Markets, Including the United Kingdom, Germany, Italy, Spain, and Portugal With the European Population of Nearly 748 Million
1, the Potential Addressable Market is More than Twice the Size of U.S. Market 10 March, London. EMMAC Life Sciences Group, Europe s largest independent cannabis company, is pleased to announce that it is has signed a definitive agreement to be acquired by Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ( Curaleaf or the Company ), a leading U.S. provider of consumer products in cannabis, for a base consideration of approximately US$285 million to be paid in 85%/15% Curaleaf shares and cash. Contingent